<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2024 19_3-4_111</article-id>
<article-id pub-id-type="doi">10.15836/ccar2024.111</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
<subj-group subj-group-type="subheading"><subject>Interdisciplinary approach to cardiovascular disease</subject></subj-group>
</article-categories>
<title-group>
<article-title>Myocardial infarction as a predictor of diffuse large B cell lymphoma?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3767-5779</contrib-id><name><surname>Holik</surname><given-names>Hrvoje</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4890-3420</contrib-id><name><surname>Vu&#x010D;ini&#x0107; Ljubi&#x010D;i&#x0107;</surname><given-names>Ivana</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-2641-6079</contrib-id><name><surname>Coha</surname><given-names>Bo&#x017E;ena</given-names></name></contrib>
<aff id="aff1"><institution>General Hospital &#x201C;Dr. Josip Ben&#x010D;evi&#x0107;&#x201D;, Slavonski Brod</institution>, <country country="hr">Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Hrvoje Holik, Op&#x0107;a bolnica &#x201C;Dr. Josip Ben&#x010D;evi&#x0107;&#x201C;, Andrije &#x0160;tampara 42, HR-35000 Slavonski Brod, Croatia. / Phone: +385-98-1833-803 / E-mail: <email xlink:href="hholik@gmail.com">hholik@gmail.com</email></corresp></author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>11</month><year>2023</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>11</month><year>2023</year></pub-date>
<volume>19</volume>
<issue>3-4</issue>
<fpage>111</fpage>
<lpage>111</lpage>
<history>
<date date-type="received"><day>14</day><month>10</month><year>2023</year></date>
<date date-type="accepted"><day>27</day><month>10</month><year>2023</year></date>
</history>
<permissions>
<copyright-statement>Croatian Cardiac Society</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>lymphoma</kwd><kwd>myocardial infarction</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction:</bold> Patients with cancer have an increased risk of both venous and arterial thromboembolism (AT) (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>). Aggressive lymphomas like the most common type - diffuse large B cell lymphoma (DLBCL) have a higher frequency of AT compared to indolent ones after diagnosis and during treatment (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r3"><italic>3</italic></xref>). However there is little information about the frequency of AT such as myocardial infarction (MI) before the diagnosis of DLBCL. Aim: To determine the prevalence of MI in DLBCL before diagnosis.</p>
<p><bold>Patients and Methods:</bold> We collected data retrospectively from DLBCL patients at the General Hospital Dr. Josip Ben&#x010D;evi&#x0107; from the beginning of 2011 by August 2023.</p>
<p><bold>Results:</bold> 59 DLBCL patients were included in this study, 33 (56%) female, median age 67 (range 28 to 82 years). Eight (13.6%) patients had MI before the DLBCL diagnosis, 6 male and 2 female. All eight patients who had a MI achieved a complete remission (CR) of the DLBCL after the planned treatment (4 patients treated with R CHOP and 4 with DA R EPOCH protocol). Seven patients are alive, with no signs of DLBCL, and 1 patient died 8 years after the end of treatment at the age of 84. The rate of CR in the entire study population was 83% after first line of treatment and 47 (63%) patients are still alive in CR. 6 patients died of DLBCL, 8 of infectious complications, while the cause of death for 8 patients is unknown. 2 patients had MI after diagnosis of DLBCL. One 5 years after the completion of chemotherapy and he previously had an MI, while the other patient developed an MI at the time of relapse of DLBCL.</p>
<p><bold>Conclusions:</bold> Our study suggests a higher prevalence of IM in patients with DLBCL (13.6%) than in general population (3.8%) (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>). Interestingly in our study is the fact that a previous MI did not negatively affect the outcome of treatment. The group of patients with a previous MI actually had a better survival compared to the entire study population. Further studies with more patients are needed to confirm this observation, and eventually to find a link between DLBCL and MI.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navi</surname><given-names>BB</given-names></name><name><surname>Reiner</surname><given-names>AS</given-names></name><name><surname>Kamel</surname><given-names>H</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Okin</surname><given-names>PM</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name><etal/></person-group> <article-title>Risk of Arterial Thromboembolism in Patients With Cancer.</article-title> <source>J Am Coll Cardiol</source>. <year>2017</year> August 22;<volume>70</volume>(<issue>8</issue>):<fpage>926</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.06.047</pub-id><pub-id pub-id-type="pmid">28818202</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>V</given-names></name><name><surname>Di Castelnuovo</surname><given-names>A</given-names></name><name><surname>Meschengieser</surname><given-names>S</given-names></name><name><surname>Lazzari</surname><given-names>MA</given-names></name><name><surname>de Gaetano</surname><given-names>G</given-names></name><name><surname>Storti</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.</article-title> <source>Blood</source>. <year>2010</year> July 1;<volume>115</volume>(<issue>26</issue>):<fpage>5322</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-01-258624</pub-id><pub-id pub-id-type="pmid">20378755</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>A</given-names></name><name><surname>Ayyappan</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Tashtish</surname><given-names>N</given-names></name><name><surname>Boughan</surname><given-names>K</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines.</article-title> <source>Hematol Oncol</source>. <year>2022</year> October;<volume>40</volume>(<issue>4</issue>):<fpage>626</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/hon.3034</pub-id><pub-id pub-id-type="pmid">35644011</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salari</surname><given-names>N</given-names></name><name><surname>Morddarvanjoghi</surname><given-names>F</given-names></name><name><surname>Abdolmaleki</surname><given-names>A</given-names></name><name><surname>Rasoulpoor</surname><given-names>S</given-names></name><name><surname>Khaleghi</surname><given-names>AA</given-names></name><name><surname>Hezarkhani</surname><given-names>LA</given-names></name><etal/></person-group> <article-title>The global prevalence of myocardial infarction: a systematic review and meta-analysis.</article-title> <source>BMC Cardiovasc Disord</source>. <year>2023</year> April 22;<volume>23</volume>(<issue>1</issue>):<fpage>206</fpage>. <pub-id pub-id-type="doi">10.1186/s12872-023-03231-w</pub-id><pub-id pub-id-type="pmid">37087452</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
